Novel Targets of Immunosuppression in Transplantation

Clin Lab Med. 2019 Mar;39(1):157-169. doi: 10.1016/j.cll.2018.10.008. Epub 2018 Dec 18.

Abstract

It is increasingly recognized that calcineurin inhibitors (CNI) such as cyclosporine and tacrolimus are not ideal immunosuppressive agents. Side effects, including increased rates of infection, hypertension, and malignancy, can be severe. Thus, in the past decade, there has been much focus on the development of novel therapeutic agents and strategies designed to replace or minimize CNI exposure in transplant patients. This article reviews potential novel targets in T cells, alloantibody-producing B cells, plasma cells, and complement in transplantation.

Keywords: B cell; Complement; Immunosuppression; Novel; Plasma cell; T cell; Target; Transplantation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Graft Rejection / immunology
  • Graft Rejection / prevention & control
  • Immunologic Factors / therapeutic use
  • Immunosuppression Therapy / methods*
  • Models, Immunological
  • T-Lymphocytes / physiology
  • Transplantation Conditioning / methods
  • Transplantation*

Substances

  • Immunologic Factors